A selection of 20 relevant publications:
- The PET-boost randomized phase II dose-escalation trial in non-small cell lung cancer. Van Elmpt W, De Ruysscher D, Van der Salm A, Lakeman A, Van der Stoep J, Emans D, Damen E, Öllers M, Sonke JJ, Belderbos J. Radiother Oncol 2012; 104:67-71
- Adaptive and innovative radiation treatment for improving cancer treatment outcome (ARTFORCE): a randomized controlled phase II trial for individualized treatment of head and neck cancer. Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C. BMC Cancer 2013.
- Evaluating tumour response of NSCLC patients with FDG-PET: potential for treatment individualization. Iuliana Toma-Dasu, Johan Uhrdin, Marta Lazzeroni, Sara Carvalho, Wouter van Elmpt, Philippe Lambin, Alexandru Dasu International Journal of Radiation Oncology Biology Physics 91:2 376–384
- Towards multidimensional radiotherapy: key challenges for treatment individualization. Iuliana Toma-Dasu and Alexandru Dasu Computational and Mathematical Methods in Medicine 934380
- Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. Oral Oncol. 2017;71:150-155.
- Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. Ou D, Adam J, Garberis I , Blanchard P, Nguyen F , Levy A, Casiraghi O, Gorphe P, Breuskin I, Janot F, Temam S, Scoazec JY, Deutsch E, Tao Y. OncoImmunology. 2017;6(9
- Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. Ou D, Garberis I , Adam J, Blanchard P, Nguyen F , Levy A, Casiraghi O, Gorphe P, Breuskin I, Janot F, Temam S, Scoazec JY, Deutsch E, Tao Y.Radiotherapy and Oncology.
- Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? Ou D, Levy A, Blanchard P, Nguyen F, Garberis I, Casiraghi O, Scoazec JY, Janot F, Temam S, Deutsch E, Tao Y. Oral Oncol. 2016 Aug;59:50-7.
- A let-7 microRNA polymorphism in the KRAS 3’-UTR is prognostic in oropharyngeal cancer. De Ruyck K, Duprez F, Ferdinande L. et al. Cancer Epidemiology . 2014, 38: 591-598
- Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I.. Cancer Res. 2016 Apr 1;76(7):1746-56.
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G. Science. 2015 Nov 20;350(6263):972-8.
- Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G. Ann Oncol. 2015 Dec;26(12):2470-7.
- Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Oncotarget. 2015 May 20;6(14):11894-909.
- Robust radiomics feature quantification using semiautomatic volumetric segmentation. Parmar C, Rios Velazquez E, Leijenaar R et al; PLoS ONE (2014); 9(7).
- Decoding tumour phenotype by noninvastive imaging using a quantitative radiomics approach. Aerts HJWL, Rios Velazquez, Leijenaar RTH et al. Nature Communications (2014, Jun 3; 5: 4006.)
- Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer. Even AJG, Reymen B, La Fontaine MD, Das M, Mottaghy FM, Belderbos JSA, De Ruysscher D, Lambin P, van Elmpt W. Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32627-0.
- Post-radiochemotherapy PET radiomics in head and neck cancer – The influence of radiomics implementation on the reproducibility of local control tumor models. Bogowicz M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, Pruschy M, Studer G, Unkelbach J, Guckenberger M, Konukoglu E, Lambin P. Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663-4.
- A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. Jochems A, El-Naqa I, Kessler M, Mayo CS, Jolly S, Matuszak M, Faivre-Finn C, Price G, Holloway L, Vinod S, Field M, Barakat MS, Thwaites D, de Ruysscher D, Dekker A, Lambin P. Acta Oncol. 2017 Oct 14:1-5.
- Radiomics: the bridge between medical imaging and personalized medicine. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Nat Rev Clin Oncol. 2017 Dec;14(12):749-762.
- Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Larue RTHM, van Timmeren JE, de Jong EEC, Feliciani G, Leijenaar RTH, Schreurs WMJ, Sosef MN, Raat FHPJ, van der Zande FHR, Das M, van Elmpt W, Lambin P. Acta Oncol. 2017 Sep 8:1-10.